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Cervical cancer is one of the most common gy-
naecological tumors, both in incidence and morbidity, 
with the incidence rates of 19.6 per 100.000 and the 
death rates of 8.8 per 1000,000 in Ukraine in 2008 
[1]. Almost 40% of patients died at first years after 
treatment that is mainly caused by the development 
of pelvic recurrence and distant metastases.
It is well known that tumor aggressiveness is strong 
associated with tumor angiogenesis which is induced 
by many factors producing both by tumor and stromal 
cells. Among the inductors of angiogenesis the most 
effective is the vascular endothelial growth factor 
(VEGF) [2, 3]. It was shown the correlation between 
level of tumor neovascularization and time to recurrence 
as well as poor clinical outcome in patients with many 
types of malignancies (gastric cancer, oesophagus 
carcinoma, ovarian cancer, breast carcinoma, colorectal 
cancer, lung cancer, etc.) [6–16]. It was determined the 
association of unfavourable prognosis for patients with 
strong expression of VEGF induced by tumor hypoxia 
that is considered as a key factor of tumor aggressive-
ness and malignant progression [13, 17–19]. At the 
same time there are controversial data concerning the 
dependence on unfavourable prognosis for patients with 
cervical cancer and VEGF expression in tumor cells.
The aim of this study was to determine the associa-
tion between VEGF expression in tumour cells and clini-
cal outcome in patients with uterine cervical cancer. 
75 patients with cervical cancer, who had been 
operated in the National Cancer Institute (Ministry 
of Health of Ukraine) from 1993 to 2008 were included 
into the retrospective study. All patients underwent 
an panhysterectomy of the 3rd type. No patient received 
chemotherapy or radiation prior to surgery. The study 
was approved by a medical Ethics Committee. The 
clinical and pathological profiles of the patients are 
presented in Table 1.
Table 1. Clinicopathologic characteristics of patients 
Characteristic No. of patients (n) No. of patients (%)
Age (years) < 50 51 68
> 50 24 32
Stage 
of disease
0 Tis 2 2 2.6 2.6
I T1AN0M0 6 39 8 52
T1BN0M0 33 44
II T2AN0M0 14 16 18.6 21.3
T2BN0M0 2 2.6
III T1BN1M0 10 16 13.3 21.3
T2AN1M0 6 8
IV T2BN1M1 2 2 2,6 2.7
Pelvic lymph 
node metastasis
Negative 57 76
Positive 18 24
Histologic type Adenocarcinoma 10 13.3
Squamous cell cancer 65 86.7
Differentiation Moderate 25 33.3
Poor 18 24
Recurrence Positive 30 40
Negative 45 60
Immunohistochemistry on VEGF expression was 
performed on deparaffinized slides using monoclonal 
antibody (clone 4H12) (DACO Cytomation, Denmark). 
The immunostained sections were observed under 
high-power magnification (x 200). The immunohis-
tochemical results for VEGF positive staining were 
evaluated as follows: the staining in less than 20% 
of cells was evaluated as low level, staining in 20–50% 
of cells — middle level, and in 50–100% of cells — 
high level of VEGF expression. Moreover, the intensity 
of staining was scored as: 1+ — weak staining; 2+ — 
moderate staining; 3+ — strong staining. 
Statistical analysis was conducted by standard soft-
ware packages of Statistica 6.0 (StatSoft Inc., USA). The 
correlation analysis was performed by the Pearson [r] 
test. The survival curves were plotted using the Kaplan-
Meier method, and the statistical significance between 
groups was determined by the log-rank test. For all 
tests, p < 0.05 was considered as significant. 
The positive staining for VEGF was determined 
in 89% of investigated tumors. The weak VEGF expres-
sion was observed in 15 (20%) neoplasms, moderate — 
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in 22 (29%), and high — in 38 (51%) (Table 2). The as-
sociation of VEGF immunopositivity in tumor cells with 
the main clinicopathological characteristics of patients 
with cervical cancer are presented in Table 3.
Table 2. VEGF expression in primary tumor 
VEGF expression level No. of patients (n) No. of patients (%)
Low and negative 15 20
Moderate 22 29
Strong 38 51
Table 3. VEGF expression level in primary tumors according 
to clinicopathologic characteristics
Clinicopathologic  characteristics
No. 
of pati-
ents
No. of VEGF-
positive tumor 
cells (%)
p
Menopausal status 
Pre (until 50 years)
Menopause (50–55 years)
Post (over 55 years)
50
12
13
58.0
63.75
52.9
> 0.05
> 0.05
> 0.05
Histological type and Differentiation
Squamous cell cancer
Moderately differentiated 
Poorly differentiated
Adenocarcinoma
Moderately differentiated 
Poorly differentiated
65
38
27
10
2
8
53.5
65.4
72.0
85.0
> 0.05
> 0.05
> 0.05
> 0.05
Lymph node metastasis
Negative
Positive
57
18
50.5
75.3
< 0.05
< 0.05
Distant metastasis
Negative
Positive
28
2
57.3
90.0
> 0.05
> 0.05
Time to recurrence
> 5 years
< 5 years
45
30
12.5
84.0
< 0.05
< 0.05
Total 75
According to some recent studies one of the main 
prognostic factors which impacts on the aggressive-
ness of cervical cancer is the age of patients [20]. 
We have observed that number of VEGF positive tumors 
in women in the age up to 50 years was 58.0 %, from 
50 to 55 years — 63.75%, and over 55 years (postmeno-
pausal period) — 52.9%. So, any significant differences 
have not been obtained between the level of VEFG ex-
pression and the age of patients (р > 0.05).
The more important prognostic factor that de-
termines prognosis for cervical cancer is the stage 
of disease [21]. In our study it was shown that the 
level of VEGF expression correlated with the stage 
of di sease (r = 0.52, p < 0.05), in particular with 
T-categories (r = 0.61, p < 0.05) (Table 4). Taking 
into account these findings and absent of common 
opinion concerning correlation between VEGF expres-
sion in cervical cancer and the stage of disease [22], 
we suggest that further investigation needs to deter-
mine VEGF expression in cervical cancer for clarifica-
tion of its association with the stages of disease.
Table 4. VEGF expression in tumors according to FIGO stages 
Stage of disease No. of patients, n (%) No. of VEGF-positive tumor cells (%)*FIGO TNM
0 Tis 2 (2.6) 2 (2.6) 45.32, 3, 4
I T1AN0M0 6 (8) 39 (52) 40.02, 3, 4
T1BN0M0 33 (44)
II T2AN0M0 14 (18.6) 16 (21.3) 80.670, 1
T2BN0M0 2 (2.6)
III T1BN1M0 10 (13.3) 16 (21.3) 80.00, 1
T2AN1M0 6 (8)
IV T2BN1M1 2 (2.6) 2 (2.7) 90.00, 1
*Statistically significant differences were noted in comparison with FIGO 
stages: 0р < 0.05 (stage 0), 1р < 0.05 (stage I), 2р < 0.05 (stage II), 3р < 0.05 
(stage III), 4р < 0.05 (stage IV).
Still now there is very disputable relation between 
the level of VEGF expression and tumour histology 
[22–24]. It was observed in our study that number 
of tumor cells shown the VEGF immunopositivity was 
detected in 55.3% among 65 squamous cell carci-
nomas and in 68.4% among 10 adenocarcinomas 
(p > 0.05) (Table 3). The nonsignificant association 
between these parameters may be explained by small 
number of patients with adenocarcinomas.
It was not revealed significant differences between 
VEGF expression in tumor and the grades of differentia-
tion (р > 0.05) (see Table 3). It was obtained the signifi-
cant correlation between high level of VEGF expression 
and pelvic lymph node status (r = 0.39, р < 0.05) that 
is in accordance with the observations of other authors 
[13], but we have not observed any association between 
VEGF expression and the distant metastasis (р > 0.05). 
It is known that cervical cancer aggressiveness im-
pact on the overall survival as well as disease-free sur-
vival. We have shown, that the level of VEGF expression 
affected both parameters of patients’ survival (Figure). 
It was determined that number of tumor cells expressed 
VEGF was 11.5% in group of patients with time to recur-
rence more than 5 years, and number of tumor cells 
expressed VEGF was 84% in a group of patients with time 
to recurrence less than 5 years (r = 0.43, р < 0.05).
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Figure. Kaplan — Meier survival curves for overall (a) and 
disease-free (b) survival in accordance to VEGF expression 
in tumor cells (p < 0.05)
Obtained results allowed to conclude that the level 
of VEGF expression in cervical cancer cells associates 
with the stage of disease, lymph node metastasis, 
and influences the disease outcome. The immuno-
histochemical evaluation of VEGF expression in tumor 
cells may be important tool to clarify the diagnosis and 
to personalize the treatment of patients with uterine 
cervical cancer. 
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